Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis

Johnson, K. E., Ceglowski, J. R., Roweth, H. ORCID: https://orcid.org/0000-0002-1100-8409, Forward, J., Tippy, M. D., El-Husayni, S., Kulenthirarajan, R., Malloy, M. W., Machlus, K. R. ORCID: https://orcid.org/0000-0002-2155-1050, Chen, W. Y., Italiano, J. E. and Battinelli, E. M. (2019) Aspirin inhibits platelets from reprogramming breast tumor cells and promoting metastasis. Blood Advances, 3 (2). pp. 198-211. ISSN 2473-9529 doi: 10.1182/bloodadvances.2018026161

Abstract/Summary

It is now recognized that compounds released from tumor cells can activate platelets, causing the release of platelet-derived factors into the tumor microenvironment. Several of these factors have been shown to directly promote neovascularization and metastasis, yet how the feedback between platelet releasate and the tumor cell affects metastatic phenotype remains largely unstudied. Here, we identify that breast tumor cells secrete high levels of interleukin 8 (IL-8, CXCL8) in response to platelet releasate, which promotes their invasive capacity. Furthermore, we found that platelets activate the Akt pathway in breast tumor cells, and inhibition of this pathway eliminated IL-8 production. We therefore hypothesized inhibiting platelets with aspirin could reverse the prometastatic effects of platelets on tumor cell signaling. Platelets treated with aspirin did not activate the Akt pathway, resulting in reduced IL-8 secretion and impaired tumor cell invasion. Of note, patients with breast cancer receiving aspirin had lower circulating IL-8, and their platelets did not increase tumor cell invasion compared with patients not receiving aspirin. Our data suggest platelets support breast tumor metastasis by inducing tumor cells to secrete IL-8. Our data further support that aspirin acts as an anticancer agent by disrupting the communication between platelets and breast tumor cells.

Item Type	Article
URI	https://centaur.reading.ac.uk/id/eprint/127728
Identification Number/DOI	10.1182/bloodadvances.2018026161
Refereed	Yes
Divisions	No Reading authors. Back catalogue items
Publisher	American Society of Hematology
Download/View statistics	View download statistics for this item